Scientists at Brown University identified a molecular mechanism that modulates glioblastoma treatment sensitivity and proposed strategies to enhance therapeutic efficacy in preclinical models. The team published findings in Cell Reports on November 10, 2025, detailing how intratumoral heterogeneity and specific signaling nodes limit response to current standard‑of‑care and targeted agents. The paper maps tumor microenvironment and cell‑intrinsic contributors to therapy resistance and demonstrates approaches that improve drug penetration or reprogram resistant cells in organoid and animal models. Developers of glioblastoma therapeutics may use these mechanistic insights to inform combination regimens, biomarker selection, and trial design.